1. Introduction {#sec1}
===============

Despite advances in implantable cardioverter-defibrillation (ICD) technology, elevated defibrillation thresholds (DFTs) occur in over 6% of patients undergoing ICD implantation [@bib1]. High thresholds present significant challenges to achieve adequate defibrillation efficacy, often requiring change in lead position [@bib2], reversal of shock polarity [@bib3], reprogramming waveform duration [@bib4], use of a high-output energy device [@bib3], or addition of superior vena cava or subcutaneous array [@bib5], [@bib6] to achieve a satisfactory defibrillation threshold. Thus, preoperative identification of patients at risk for elevated DFTs can facilitate ICD procedure planning.

Methamphetamine, a growing drug of abuse [@bib7] is associated with increased non-ischemic dilated cardiomyopathy [@bib8], [@bib9], [@bib10] and sudden death [@bib11], [@bib12]. Methamphetamine abuse is associated with a number of cardiac pathologic changes [@bib13] including hypertrophy, myocardial disarray, and fibrosis [@bib14]. An increasing number of these patients are referred for ICD implantation for primary and secondary indications.

Clinically, we have observed a high prevalence of elevated DFTs in these patients. We hypothesized that patients with methamphetamine cardiomyopathy (MACMP) have higher defibrillation thresholds than controls. Furthermore, we hypothesized that these patients more frequently require significant changes to ICD implantation procedure, including use of high energy devices to provide effective defibrillation therapy.

2. Methods {#sec2}
==========

This study is a retrospective, case-control study, performed with the approval of the local Institutional Review Board.

2.1. Data collection {#sec2.1}
--------------------

We identified 10 patients from the medical record with documented methamphetamine cardiomyopathy who underwent first ICD implantation at the university hospital between November 2003 to December 2007. We then evaluated 79 patients (18 women and 61 men, mean age 59.60 ± 5.13) who underwent first ICD implantation without MACMP between December 2005 and November 2007 as potential control patients, and matched cases versus controls for age and sex. Patient characteristic including age, sex, body surface area, electrocardiogram (ECG) parameters, B-type natriuretic peptide (BNP), left ventricular ejection fraction (LVEF), DFT, and use of high output ICD during device implantation for both case and control groups were recorded and compared.

2.2. Defibrillation threshold testing {#sec2.2}
-------------------------------------

All patients included in the study were subjected to clinical DFT testing during ICD implantation. DFT was measured using a step-down protocol (i.e. step-wise reduction of Direct-Current (DC) shock strength during serial inductions of ventricular fibrillation (VF), until the ICD shock fails to cardiovert VF).

2.3. Events during ICD implantation {#sec2.3}
-----------------------------------

We reviewed the operative reports from all patients to determine what impact higher DFTs had upon ICD implantation procedures. Events recorded included change in defibrillation vector, use of high energy ICD pulse generator (≥35 J delivered), and use of subcutaneous array.

### 2.3.1. Evaluation for possible confounders {#sec2.3.1}

We evaluated the correlation between DFT and potential confounders for using the cohort of patients in the study. We then adjusted the comparison of methamphetamine versus matched control patients to determine if the difference remained significant.

2.4. Statistical analysis {#sec2.4}
-------------------------

Continuous data are represented as mean ± standard deviation (SD). The characteristics of patients in both groups were compared through use of paired *t*-test for numerical data and the McNemar\'s test for nominal data. Proportions were compared using Fisher\'s exact test. Analysis of covariance was used to adjust for other sources of variation to DFT. Linear regression was used to evaluate DFT versus LVEF and log (BNP). All tests were two sided and differences were considered statistically significant if the null hypothesis could be rejected with more than 95% confidence (P \< 0.05) Statistical analysis was performed using NCSS 2007 (Kaysville, UT).

3. Results {#sec3}
==========

Compared to age- and sex-matched controls, the methamphetamine group (n = 10, age 44.2 years, 7 male) showed significantly elevated BNP (Log BNP 2.88 ± 0.49 vs 2.00 ± 0.72, p = 0.02) and reduced LVEF (17.9 ± 9.4 vs 35.9 ± 15.2, p = 0.02) at baseline prior to device implantation ([Table 1](#tbl1){ref-type="table"}). There were no significant differences in body surface area and bi-ventricular ICD implantation or ECG indices including: heart rate, PR, QRS and QTc intervals. Overall, both groups were well matched in use of amiodarone, class I anti-arrhythmics, beta-blockers, and ACE inhibitors.Table 1Characteristics of patients using meth vs. patients not using meth.Table 1CharacteristicPatients using meth (N = 10)Patients not using meth (N = 10)P ValueAge at DFT, yr.44.2 ± 8.444.2 ± 9.3MatchedMale Gender, n(%)7 (70%)6 (60%)NSDefibrillation Threshold, J23.7 ± 6.714.7 ± 4.6**\<0.005**PR Interval, ms189 ± 39154 ± 380.06QRS Interval, ms122 ± 31109 ± 310.37QTc Interval, ms470 ± 41446 ± 360.26Ventricular rate93 ± 2882 ± 140.3Ejection Fraction, %17.8 ± 9.435.9 ± 15.2**0.02**BNP1173 ± 784260 ± 349**0.02**- Log (BNP)2.88 ± 0.492.00 ± 0.72**0.02**Body Surface Area, m^2^1.82 ± 0.141.98 ± 0.380.18Biventricular ICD, n(%)4 (40%)2 (20%)0.62Amiodarone, n(%)0 (0%)1 (10%)NSClass I AA, n(%)0 (0%)0 (0%)NSACEi or ARB, n(%)8 (80%)9 (90%)NSBeta-blockers, n(%)7 (70%)8 (80%)NS

3.1. Elevated defibrillation threshold and effects on ICD procedure {#sec3.1}
-------------------------------------------------------------------

The mean DFT of patients with history of methamphetamine was significantly greater than controls (23.7 ± 6.7 vs 14.7 ± 4.6, p \< 0.005, [Fig. 1](#fig1){ref-type="fig"}). Due to their elevated DFT, a total of 5 patients (50%) received a high energy ICD pulse generator. In contrast, none (p = 0.033) of controls required high energy devices to achieve an acceptable safety margin.Fig. 1Comparison of defibrillation thresholds (DFTs) between control and methamphetamine cardiomyopathy (MACMP) patients is shown. Significantly higher DFTs were found in the MACMP population (23.7 ± 6.7 vs 14.7 ± 4.6, p \< 0.005).Fig. 1

3.2. Evaluation of DFT versus LVEF and log (BNP) {#sec3.2}
------------------------------------------------

Because there were significant differences between MACMP and control patients in LVEF and log (BNP), we attempted to determine if differences in DFT persisted after adjusting for these variables. Interestingly, there was no significant relationship between DFT and LVEF for the entire study population ([Fig. 2](#fig2){ref-type="fig"}), including methamphetamine patients. There was a weak relationship between DFT and log (BNP) ([Fig. 3](#fig3){ref-type="fig"}). However, this accounted for only a small portion of the observed variability in DFT, given the low slope of the correlation and the low R-squared value.Fig. 2There was a significant relationship between left ventricular ejection fraction (LVEF) and defibrillation threshold (DFT) for the population (DFT = 19.8689--0.0910 (LVEF), p = 0.045). However, this relationship accounted for only a fraction of the variation, as R-squared was 0.0453.Fig. 2Fig. 3No relationship was found between log (B-type natriuretic peptide (BNP)) and defibrillation threshold (DFT) for the population (DFT = 11.3305 + 2.3975 (log(BNP)), p = 0.08). The correlation was poor, with R-squared of 0.041.Fig. 3

Differences in DFT between patients with and without MACMP persisted even after comparisons were adjusted for log (BNP). Further adjustment for differences in LVEF also did not affect the significance of the results.

4. Discussion {#sec4}
=============

The findings of this study confirm the hypothesis that patients with MACMP have significantly elevated DFTs at ICD implantation. This represents an important addition to the list of subgroups presenting for device therapy already shown to have high DFTs, including patients with cocaine abuse [@bib15], hypertrophic cardiomyopathy [@bib16], [@bib17], and amiodarone therapy [@bib1], [@bib18], [@bib19], [@bib20], among others. Although, there is some debate about routine DFT testing for all ICD implantation procedures [@bib1], [@bib21] due to complications including prolonged hypotension, hypoperfusion and circulatory arrest, thromboembolic episodes, and use of heavier sedation [@bib21]. Also, recent randomized controlled study among 145 patients with heart failure and severe LV dysfunction revealed no significant differences in perioperative complications, failed appropriate shocks, or arrhythmic death, among those with and without intraoperative DFT [@bib22]. However, there are certain group of high risk patients who requires DFT testing to assure effective defibrillation therapy, based on the fact that a standard 31 J ICD would be unable to unable to provide a 10 J safety margin to a majority of patients with high defibrillation threshold including our MACMP population (average DFT 24 J).

While MACMP patients in our study had evidence of more advanced congestive heart failure, adjusting for these variables did not affect the significance of the results. This is not surprising, given the variable findings within the literature on the effect of left ventricular dysfunction on DFT. In particular, studies by Shukla et al. [@bib23] and Lubinski et al. [@bib20] both found that low LVEF predicted higher DFTs. In contrast, Epistein et al. [@bib18] found no clinical characteristic other than amiodarone use could consistently predict elevated DFT. The mechanism behind MACMP is multifactorial and may be attributed to direct toxicity, catecholamine excess, coronary vasospasm, increases in reactive oxygen species (ROS), mitochondrial injury, and changes in myocardial metabolism. The above mentioned etiologies along with degree of LV fibrosis and autonomic dysregulation due to sympathomimetic substance abuse may be responsible for increased defibrillation energy requirements.

It is interesting to note that the findings of this study are in close agreement with the findings of Chen et al. [@bib15] regarding the effects of cocaine, also a powerful sympathomimetic agent, on DFT thresholds. Previous work, although conflicting, has shown the effects of circulating catecholamines on DFT [@bib24], [@bib25]. Future work is required to determine if changes in autonomic function underlie the electrophysiologic mechanisms of VF reinitiation following failed defibrillation.

Our study showed significant changes to the ICD implantation procedure for a high risk population. This has important implications for procedure planning. Given the high cost ICD pulse generators, it may be economically advantageous to empirically select high output devices for this population rather than a standard output ICD, given that unsuccessful devices are not reusable for other patients, and must be recycled. However, prospective cost-effectiveness studies are required to definitively answer this question.

5. Conclusions {#sec5}
==============

Planning for ICD implantation should take into consideration a history of methamphetamine abuse, mandating DFT testing and consideration of empiric high energy devices for such patients.
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